全文获取类型
收费全文 | 55篇 |
免费 | 0篇 |
专业分类
妇产科学 | 1篇 |
基础医学 | 10篇 |
临床医学 | 3篇 |
内科学 | 4篇 |
外科学 | 16篇 |
预防医学 | 1篇 |
药学 | 3篇 |
肿瘤学 | 17篇 |
出版年
2021年 | 2篇 |
2019年 | 1篇 |
2014年 | 2篇 |
2013年 | 2篇 |
2012年 | 4篇 |
2011年 | 2篇 |
2010年 | 2篇 |
2009年 | 2篇 |
2008年 | 2篇 |
2007年 | 1篇 |
2006年 | 3篇 |
2005年 | 3篇 |
2004年 | 1篇 |
2003年 | 1篇 |
2002年 | 2篇 |
2001年 | 3篇 |
2000年 | 2篇 |
1999年 | 4篇 |
1997年 | 1篇 |
1996年 | 2篇 |
1995年 | 3篇 |
1993年 | 1篇 |
1990年 | 2篇 |
1988年 | 2篇 |
1986年 | 1篇 |
1981年 | 2篇 |
1978年 | 1篇 |
1976年 | 1篇 |
排序方式: 共有55条查询结果,搜索用时 15 毫秒
1.
Expression and function of galectin-3, a beta-galactoside-binding protein in activated T lymphocytes
Joo HG Goedegebuure PS Sadanaga N Nagoshi M von Bernstorff W Eberlein TJ 《Journal of leukocyte biology》2001,69(4):555-564
A soluble beta-galactoside-binding lectin, galectin-3 has been shown to be involved in cell adhesion and activation of immune cells. Although galectin-3 is known to be expressed in various types of cells, it has not been shown whether galectin-3 is expressed in T lymphocytes. We present evidence here that galectin-3 is expressed in activated murine T lymphocytes including CD4+ and CD8+ T cells but not in resting T cells. Galectin-3 expression was induced by anti-CD3 mAb or mitogen and enhanced by common gamma-chain signaling cytokines, IL-2, IL-4, and IL-7, in activated T lymphocytes, whereas the inflammatory cytokines including TNF-alpha and IFN-gamma did not. Galectin-3 expression and proliferation were down-regulated by withdrawal of IL-2 and gamma irradiation. Antisense but not sense phosphorothioated oligonucleotides for galectin-3 inhibited galectin-3 expression and blocked proliferation of T cells significantly. This study suggests that up-regulation of galectin-3 plays an important role in proliferation of activated T lymphocytes. 相似文献
2.
3.
Lobular capillary haemangiomas in the gingiva near the mandibular incisor region of two 6-month-old calves are described. 相似文献
4.
5.
Ruben S.A. Goedegebuure Madelon Q. Wentink Hans J. van der Vliet Peter Timmerman Arjan W. Griffioen Tanja D. de Gruijl Henk M.W. Verheul 《The oncologist》2021,26(2):e218-e229
Lessons Learned
- The novel therapeutic vaccine hVEGF26–104/RFASE was found to be safe and well tolerated in patients with cancer.
- hVEGF26–104/RFASE failed to induce seroconversion against native hVEGF165 and, accordingly, neither a decrease in circulating vascular endothelial growth factor (VEGF) levels nor clinical benefit was observed.
- Remarkably, hVEGF26–104/RFASE induced VEGF165-neutralizing antibodies in a nonhuman primate model. The absence of seroconversion in human calls for caution in the interpretation of efficacy of human vaccines in nonhuman primates.
6.
Lijin Li John M. Herndon Steven M. Truscott Ted H. Hansen Timothy P. Fleming Peter Goedegebuure William E. Gillanders 《Vaccine》2010
It is commonly believed that delivery of antigen into the class I antigen presentation pathway is a limiting factor in the clinical translation of DNA vaccines. This is of particular concern in the context of cancer vaccine development as many immunodominant peptides derived from self tumor antigens are not processed and presented efficiently. To address this limitation, we have engineered completely assembled peptide/MHC class I complexes whereby all three components (class I heavy chain, β2m, and peptide) are attached by flexible linkers and expressed as a single polypeptide (single chain trimers or SCT). In this study, we tested the efficacy of progressive generations of SCT DNA vaccines engineered to (1) enhance peptide binding, (2) enhance interaction with the CD8 coreceptor, and/or (3) activate CD4+ helper T cells. Disulfide trap SCT (dtSCT) have been engineered to improve peptide binding, with mutations designed to create a disulfide bond between the class I heavy chain and the peptide linker. dtSCT DNA vaccines dramatically enhance the immune response to model low affinity antigens as measured by ELISPOT analysis and tumor challenge. SCT engineered to enhance interaction with the CD8 coreceptor have a higher affinity for the TCR/CD8 complex, and are associated with more robust CD8+ T cell responses following vaccination. Finally, SCT constructs that coexpress a universal helper epitope PADRE, dramatically enhance CD8+ T cell responses. Taken together, our data demonstrate that dtSCT DNA vaccines coexpressing a universal CD4 epitope are highly effective in generating immune responses to poorly processed and presented cancer antigens. 相似文献
7.
TAT-Bim Induces Extensive Apoptosis in Cancer Cells 总被引:2,自引:0,他引:2
Kashiwagi H McDunn JE Goedegebuure PS Gaffney MC Chang K Trinkaus K Piwnica-Worms D Hotchkiss RS Hawkins WG 《Annals of surgical oncology》2007,14(5):1763-1771
Background Suppression of apoptosis is central to the development of cancer and is associated with resistance to modern adjuvant treatments.
Therefore, molecules and pathways of apoptotic processes are critical targets for the development of anti-cancer therapeutics.
Since apoptosis is executed by intracellular proteins, molecular approaches must incorporate a method to deliver the treatment
into the tumor cells.
Methods We utilized a peptide that contains two domains, a peptide transduction domain derived from the HIV-1 TAT protein and a biological
effector domain, the BH3 domain from the pro-apoptotic Bcl-2 family member Bim. We examined whether this construct (TAT-Bim)
induced apoptosis in several cancer cell lines (T-cell lymphoma (EL4), pancreatic cancer (Panc-02), and melanoma (B16)) and
whether TAT-Bim treatment synergized with radiation. A mutant TAT-Bim peptide with no biologic activity (TAT-Bim-inactive)
was used as a control. C57/BL6 mice were challenged with syngeneic cancer cell lines and the effects of intratumoral TAT-Bim
injection on tumor growth and host survival were determined.
Results TAT-Bim was internalized by all cancer cells within two hours. TAT-Bim resulted in apoptosis in a dose dependent fashion in
all cell lines and sublethal irradiation augmented the effects of TAT-Bim induced apoptosis. TAT-Bim significantly slowed
tumor growth in murine models of pancreatic cancer and melanoma.
Conclusion TAT-Bim exemplifies a strategy for cancer therapy that involves inducing apoptosis by antagonizing the endogenous anti-apoptotic
machinery. Small peptide therapeutics, in combination with traditional adjuvant therapies such as radiation, may provide a
valuable ‘second hit’ and drive tumor cells into programmed cell death.
This work was presented in part at the Annual Meeting of the Society for Surgical Oncology Cancer Forum, San Diego 2006 相似文献
8.
John R Hornick Suwanna Vangveravong Dirk Spitzer Carmen Abate Francesco Berardi Peter Goedegebuure Robert H Mach William G Hawkins 《Journal of experimental & clinical cancer research : CR》2012,31(1):41
Background
Sigma-2 receptor ligands have been studied for treatment of pancreatic cancer because they are preferentially internalized by proliferating cells and induce apoptosis. This mechanism of apoptosis is poorly understood, with varying reports of caspase-3 dependence. We evaluated multiple sigma-2 receptor ligands in this study, each shown to decrease tumor burden in preclinical models of human pancreatic cancer.Results
Fluorescently labeled sigma-2 receptor ligands of two classes (derivatives of SW43 and PB282) localize to cell membrane components in Bxpc3 and Aspc1 pancreatic cancer cells and accumulate in lysosomes. We found that interactions in the lysosome are critical for cell death following sigma-2 ligand treatment because selective inhibition of a protective lysosomal membrane glycoprotein, LAMP1, with shRNA greatly reduced the viability of cells following treatment. Sigma-2 ligands induced lysosomal membrane permeabilization (LMP) and protease translocation triggering downstream effectors of apoptosis. Subsequently, cellular oxidative stress was greatly increased following treatment with SW43, and the hydrophilic antioxidant N-acetylcysteine (NAC) gave greater protection against this than a lipophilic antioxidant, α-tocopherol (α-toco). Conversely, PB282-mediated cytotoxicity relied less on cellular oxidation, even though α-toco did provide protection from this ligand. In addition, we found that caspase-3 induction was not as significantly inhibited by cathepsin inhibitors as by antioxidants. Both NAC and α-toco protected against caspase-3 induction following PB282 treatment, while only NAC offered protection following SW43 treatment. The caspase-3 inhibitor DEVD-FMK offered significant protection from PB282, but not SW43.Conclusions
Sigma-2 ligand SW43 commits pancreatic cancer cells to death by a caspase-independent process involving LMP and oxidative stress which is protected from by NAC. PB282 however undergoes a caspase-dependent death following LMP protected by DEVD-FMK and α-toco, which is also known to stabilize the mitochondrial membrane during apoptotic stimuli. These differences in mechanism are likely dependent on the structural class of the compounds versus the inherent sigma-2 binding affinity. As resistance of pancreatic cancers to specific apoptotic stimuli from chemotherapy is better appreciated, and patient-tailored treatments become more available, ligands with high sigma-2 receptor affinity should be chosen based on sensitivities to apoptotic pathways. 相似文献9.
Increased prevalence of regulatory T cells (Treg) is induced by pancreas adenocarcinoma 总被引:5,自引:0,他引:5
Liyanage UK Goedegebuure PS Moore TT Viehl CT Moo-Young TA Larson JW Frey DM Ehlers JP Eberlein TJ Linehan DC 《Journal of immunotherapy (Hagerstown, Md. : 1997)》2006,29(4):416-424
We reported earlier that patients with breast or pancreas cancer have an increased prevalence of regulatory T cells (Treg) in the blood and tumor draining lymph nodes (TDLNs) compared with healthy individuals. In the current study, we tested the hypothesis that tumor cells promote the prevalence of Treg. The transforming growth factor-beta (TGF-beta) secreting murine pancreas adenocarcinoma, Pan02 cell line was injected into syngeneic C57BL/6 mice and the prevalence of Treg in the TDLNs and tumor spleen was measured weekly. Compared with control mice, the prevalence of CD25+ CD4+ cells in TDLNs and in tumor spleen increased with tumor growth. Analysis of these CD25+ CD4+ T cells in vitro confirmed expression of the Treg marker, Foxp3. In addition, their functional activity resembled that of Treg, as evidenced by a poor proliferative capacity; suppression of proliferation of CD25- CD4 or CD8T cells and inhibition of interferon-gamma release by CD25- CD4+ T cells. Reconstitution of Pan02-bearing Rag-/- mice with naive syngeneic CD25- CD4+ T cells induced CD25+ CD4+ Foxp3+ T cells in TDLNs, but not in the spleen. In contrast, Foxp3 was not detected in unreconstituted Pan02-bearing Rag-/- mice, or reconstituted mice bearing a TGF-beta-negative esophageal tumor. Furthermore, administration of neutralizing anti-TGF-beta antibody blocked the induction of Foxp3 in reconstituted Pan02-bearing Rag-/- mice. These results mimic earlier in vitro studies showing induction of Foxp3 through CD3 plus CD28 stimulation in the presence of TGF-beta. We conclude that Pan02 tumor promotes the prevalence of Treg, in part through the secretion of TGF-beta, which may result in immune evasion. 相似文献
10.
J H Vos J S van der Linde-Sipman S A Goedegebuure 《Journal of comparative pathology》1986,96(3):335-341
Two cases of feline myopathy are described which were associated with moderate locomotor disturbances. At necropsy, a pale coloured skeletal musculature was found with severe hypertrophy of diaphragmatic musculature. Histologically, the myopathy was characterized by varying fibre diameter, internal nuclei, moderate degeneration and necrosis of solitary muscle fibres and slight to moderate endomysial and perimysial fibrosis. Only very few regenerating muscle fibres were present. The histological findings are compatible with those found in human muscular dystrophies and so this feline myopathy may be considered as a dystrophy-like myopathy. 相似文献